Glatiramer
1 NDC across 1 manufacturer|1 Generic,0 Brand
Glatiramer is used to treat relapsing-remitting multiple sclerosis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
Glatiramer is available as 1 NDC from 1 manufacturer (1 generic, 0 brand), with NADAC prices from $86.10 to $86.10 per ML. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
1G / 0B
Manufacturers
1
competing in market
Price Spread
$86.10 – $86.10
per ML
7d Activity
avg -5.5% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Mylan Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing GLATIRAMER
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
GLATIRAMER 40 MG/ML SYRINGE | $86.0952 per ML | -5.47% |
Frequently Asked Questions
What is Glatiramer used to treat?
Glatiramer is used to treat relapsing-remitting multiple sclerosis, per the National Library of Medicine's MED-RT classification.
How many Glatiramer products are on the market?
The Glatiramer drug market contains 1 NDC from 1 manufacturer — 1 generic and 0 brand products.
What is the price range for Glatiramer?
NADAC reference prices for Glatiramer range from $86.0952 to $86.0952 per ML.
Which manufacturers make Glatiramer?
1 manufacturer lists Glatiramer in NADAC. Ranked by number of NDCs, the largest are Mylan Pharmaceuticals Inc. (1).
How has the price of Glatiramer changed recently?
Over the past 7 days, 0 Glatiramer NDCs rose and 1 fell, with a market-wide average change of -5.5%.